Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Solid tumor that is metastatic, locally advanced or recurrent
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Life expectancy greater than or equal to (\>/=) 12 weeks
Measurable disease, as defined by RECIST v 1.1
Adequate hematologic and end organ function
Use of highly effective contraception
Histological tumor tissue specimen
Participants enrolling in the indication-specific expansion cohorts in Stage 2 must consent to tumor biopsies and must have one of the following types of cancer:
* Metatastic colorectal cancer
* Non-small cell lung cancer
* Melanoma
You may not be if
Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment
Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment
Known active or untreated central nervous system (CNS) metastases
Leptomeningeal disease
Uncontrolled tumor-related pain or uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent (once monthly or more frequently) drainage procedures
Uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab
Pregnant and lactating women
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cell or any component of the atezolizumab formulation
History of autoimmune disease
Participants with prior allogeneic stem cell or solid organ transplantation
Positive test for human immunodeficiency virus (HIV)
Participants with active hepatitis B, hepatitis C, or tuberculosis
Severe infections within 4 weeks prior to Cycle 1 Day 1
Signs or symptoms of infection within 2 weeks prior to Cycle 1 Day 1
Received therapeutic oral or IV antibiotics within 2 weeks prior to Cycle 1 Day 1
Significant cardiovascular disease
Major surgical procedure other than for diagnosis within 28 days prior to Cycle 1 Day 1 or anticipation of need for a major surgical procedure during the course of the study
Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1
History of prior significant toxicity from another mitogen-activated protein kinase (MEK) pathway inhibitor requiring discontinuation of treatment
Allergy or hypersensitivity to components of the cobimetinib formulations
History of congenital long QT syndrome or corrected QT interval (QTc) greater than (\>) 450 milliseconds at screening
Left ventricular ejection fraction (LVEF) below institutional lower limit of normal (LLN) or below 50%, whichever is lower, as determined by echocardiogram or Multi Gated Acquisition Scan (MUGA) scan
History of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment, central serous chorioretinopathy (CSCR), retinal vein occlusion (RVO), or neovascular macular degeneration
History of malabsorption syndrome or other condition that would interfere with enteral absorption
Prior treatment with clusters of differentiation (CD) 137 agonists or immune checkpoint blockade therapies, systemic immunostimulatory agents, or systemic immunosuppressive medications
Clareo Health | Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors
